MA-2029 is a selective, orally bioactive and competitive motilin receptor blocker (antagonist) (IC50=4.9 nM). MA-2029 is selective for the motilin receptor over other receptors and ion channels. MA-2029 is indicated for gastrointestinal diseases associated with gastrointestinal motility disorders.

Physicochemical Properties

Molecular Formula	C31H46CLFN4O4
Molecular Weight	593.17275094986
Exact Mass	556.342
CAS #	287206-61-5
PubChem CID	10144175
Appearance	White to off-white solid powder
LogP	5.1
Hydrogen Bond Donor Count	4
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	13
Heavy Atom Count	40
Complexity	825
Defined Atom Stereocenter Count	3
SMILES	Cl.CCNC([C@H](CC1C=CC(O)=C(C(C)(C)C)C=1)NC([C@@H](N(C([C@H](CC1=CC=C(F)C=C1)NC)=O)C)C(C)C)=O)=O
InChi Key	KSDWAJPUTRBIRR-KLJDGLGGSA-N
InChi Code	InChI=1S/C31H45FN4O4/c1-9-34-28(38)24(18-21-12-15-26(37)23(16-21)31(4,5)6)35-29(39)27(19(2)3)36(8)30(40)25(33-7)17-20-10-13-22(32)14-11-20/h10-16,19,24-25,27,33,37H,9,17-18H2,1-8H3,(H,34,38)(H,35,39)/t24-,25-,27-/m0/s1
Chemical Name	(2S)-N-[(2S)-3-(3-tert-butyl-4-hydroxyphenyl)-1-(ethylamino)-1-oxopropan-2-yl]-2-[[(2S)-3-(4-fluorophenyl)-2-(methylamino)propanoyl]-methylamino]-3-methylbutanamide
Synonyms	MA2029; MA 2029; MA-2029
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vitro	The contraction of isolated rabbit duodenum longitudinal muscle strips elicited by motilin is competitively inhibited by MA-2029 (1 to 30 nM), showing a pA2 value of 9.17˱0.01. Even at a dosage of 1 μM MA-2029, contractile responses to substance P and acetylcholine remained unaltered. Rabbit colonic smooth muscle tissue and HEK 293 cell membrane homogenates expressing human motilin receptors are subject to concentration-dependent inhibition of [125I]motilin binding by MA-2029. pKi for MA-2029 is 8.38 in HEK 293 cells and 8.58±0.04 in rabbit colon homogenate [1].
ln Vivo	The number of abdominal muscular contractions elicited under the same conditions is dosage-dependently inhibited by MA-2029 (0.3-3 mg/kg; oral), with a dose of 3 mg/kg causing a considerable suppression [1]. The oral MA-2029 (10 mg/kg) therapy showed a t1/2 of two hours [1]. When 3 mg/kg or more is administered, significant inhibition happens 30 minutes later, and when 10 mg/kg or more is administered, it happens 4 hours later (MA-2029). As a result, the inhibitory action starts to take effect 30 minutes after administering 10 mg/kg or greater, or at least 4 hours later [ 1].
Animal Protocol	Animal/Disease Models: Male Japanese white rabbit (approximately 2-3 kg) [1] Doses: 0.3, 1, 3 mg/kg Route of Administration: Oral Experimental Results:Dose-dependent inhibition of the number of abdominal muscle contractions induced under the same conditions. 3 mg/kg caused significant inhibition. Animal/Disease Models: Male Japanese white rabbit (approximately 2-3 kg) [1] Doses: 10 mg/kg Route of Administration: Oral (pharmacokinetic/PK/PK analysis) Experimental Results: t1/2 is 2 hrs (hrs (hours)).
References	[1]. Oral administration of MA-2029, a novel selective and competitive motilin receptor antagonist, inhibits motilin-induced intestinal contractions and visceral pain in rabbits. Eur J Pharmacol. 2008 Mar 10;581(3):296-305.
Additional Infomation	See also: MA-2029 (annotation moved to).

Solubility Data

Solubility (In Vitro)

May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples

Solubility (In Vivo)

Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	1.6859 mL	8.4293 mL	16.8586 mL
	5 mM	0.3372 mL	1.6859 mL	3.3717 mL
	10 mM	0.1686 mL	0.8429 mL	1.6859 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.